Biomarkers for neurodegenerative disorders
The present invention provides methods for diagnosing neurodegenerative disease, such as Alzheimer's Disease, Parkinson's Disease, and dementia with Lewy body disease by detecting a pattern of gene product expression in a cerebrospinal fluid sample and comparing the pattern of gene product expression from the sample to a library of gene product expression pattern known to be indicative of the presence or absence of a neurodegenerative disease. The methods also provide for monitoring neurodegenerative disease progression and assessing the effects of therapeutic treatment. Also provided are kits, systems and devices for practicing the subject methods.
1. A method for detecting presence or absence of Alzheimer's disease, Parkinson's disease, or dementia with Lewy body disease in a subject having signs or symptoms suggesting cognitive decline or neurological disease, said method comprising:
detecting a pattern of gene product expression for at least five gene products listed in FIGS. 5 A- 5 YY in a cerebrospinal fluid sample obtained from a subject; and
comparing the detected pattern of gene product expression from the cerebrospinal fluid sample to a library of gene product expression pattern known to be indicative of the presence or absence of a neurodegenerative disease as represented in FIGS. 5 A- 5 YY,
wherein when the detected pattern corresponds to a pattern corresponding to a pattern presented by Alzheimer's disease, Parkinson's disease, or dementia with Lewy body disease as represented in FIGS. 5 A- 5 YY a determination of the presence or absence of Alzheimer's disease, Parkinson's disease, or dementia with Lewy body disease is made.
2. The method of claim 1 , wherein said gene product is a polypeptide.
3. The method of claim 1 , wherein said detecting is by mass spectrometry.
4. The method of claim 1 , wherein said detecting is by immunoassay.
5. The method of claim 4 , wherein said immunoassay is enzyme linked immunosorbent assay (ELISA).
6. The method of claim 1 , wherein said detecting is by an antibody-derivatized bead-based technology.